A Retrospective Study Investigating the Efficacy and Safety of Immune Checkpoint Inhibitors in Elderly, Advanced Non-Small Cell Lung Cancer Patients
Latest Information Update: 18 Jun 2018
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Jun 2018 New trial record
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.